COMMUNIQUÉS West-GlobeNewswire

FountainRx Selects Inovalon’s ScriptMed® Software To Enhance Patient Care and Scale Specialty and Infusion Pharmacy Services
16/04/2024
ScriptMed Cloud-Based SaaS Software Enables Data-Driven Workflows and Provides More Personalized, Cost-Effective Care for Patients with Complex Health Conditions BOWIE, Md., April 16, 2024 (GLOBE NEWSWIRE) -- Inovalon [...]
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
16/04/2024
Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines [...]
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
16/04/2024
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: [...]
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
16/04/2024
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and [...]
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
16/04/2024
CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
Southern California Clinic Signs Multi-Year Deal for MedMatrix AI Platform
16/04/2024
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF, FSE:Y30) today announced that Dermatology Institute & Skin Care [...]
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
16/04/2024
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned [...]
SAB Biotherapeutics Provides SAB-142 Trial Update
16/04/2024
MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
16/04/2024
Company Announcement Net sales of DARZALEX ® in the first quarter of 2024 totaled USD 2,692 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 16, [...]
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
16/04/2024
Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV® Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launches R&D expenditures increase by 14.2% to EUR 5.8 bn Boehringer [...]
CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer
16/04/2024
Company plans to launch FDA IND enabling studies needed to apply for approval to proceed with human trials Santa Barbara, April 16, 2024 (GLOBE NEWSWIRE) -- Santa Barbara, CA, April 16, 2024 (GLOBE NEWSWIRE) -- [...]
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16/04/2024
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful completion of a long-term [...]
Faron Confirms Plans for the Coming Months Under New Leadership
16/04/2024
Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next month Incoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS [...]
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
16/04/2024
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Halle (Saale) / Munich, Germany, April 16, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
16/04/2024
ADHERE data show VYVGART ® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of [...]
StateHouse Appoints Felicia Snyder as Independent Chair of the Board
16/04/2024
Provides Update on Annual Filings Timing SAN DIEGO and TORONTO, April 15, 2024 (GLOBE NEWSWIRE) -- StateHouse Holdings Inc . (“StateHouse” or the “Company”) (CSE: STHZ) (OTCQB: STHZF), a California-focused, vertically [...]
Foundation for Sarcoidosis Research and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education for April Awareness Month
16/04/2024
CHICAGO, April 15, 2024 (GLOBE NEWSWIRE) -- Beginning April 15 th , Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare [...]
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation
16/04/2024
FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging Collaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial [...]
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
15/04/2024
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway [...]

Pages